Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model
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MATERIALS AND METHODS
Viral production
4T1 cells were seeded in a 12-well plate at 5 × 10 4 cells/well, and infected with RdB at MOI 0.5. At 4, 48, and 72 hr post-infection, both supernatant and cells were collected. The copy number of Ad genomes was measured by real-time quantitative PCR (TaqMan PCR detection; Applied Biosystems, Foster City, CA) as previously described [78] (Supplementary Figure S2) .
Expression levels of CAR in 4T1 cells
The expression levels of coxsackievirus and adenovirus receptor (CAR) on the surface of 4T1 cells were determined by flow cytometry. Cells were harvested by trypsin-EDTA treatment and washed with PBS (pH 7.4) containing 1% FBS. Cells were then incubated with fluorescein isothiocyanate-conjugated anti-CAR Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C for 1 hr. Cells were washed two times with PBS containing 1% FBS. Flow cytometry was performed using the FACSCalibur analyzer (BD Biosciences, San Jose, CA) with Cell Quest software (BD Biosciences) (Supplementary Table S1 ).
Assessment of in vivo toxicity
To measure in vivo toxicity of each oncolytic Ads, mice were administrated intratumorally with 2 × 10 10 VP of RdB, RdB/IL12, RdB/DCN, or RdB/IL12/DCN along with PBS as a control. Serum levels of aspartate aminotransferase (AST) and alanine transaminase (ALT) were then measured at 6 days post injection (Supplementary Table S2 ). 
